AVIR Atea Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Atea Pharmaceuticals is trading 10.71% down in pre-market with no clear company-specific catalyst identified
Atea Pharmaceuticals is trading 10.71% down at $4.92 after no clear company-specific catalyst was identified for August 25, 2026. - The latest official...
🟢 Atea Pharmaceuticals rises 5.5% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🟢 Atea Pharmaceuticals is trading 5% up today after BEM/RZR met Phase 3 HCV endpoint
Atea Pharmaceuticals is trading 5.14% up now at $5.32 after investors digested August 12, 2026, earnings and encouraging hepatitis C trial data. - Reported a...
Atea Pharmaceuticals second quarter 2026 loss of $0.41 per share beat estimates by $0.15
Atea Pharmaceuticals reported zero revenue for the second quarter of 2026, which is consistent with its status as a clinical-stage biopharmaceutical company....
Atea Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Atea Pharmaceuticals is expected to report a Q2 2026 consensus loss of $0.56 per share on $0.00 in revenue, with its current stock price of approximately $4.61...
🟢 Atea Pharmaceuticals is trading 5% up today amid broader biotech rally
Atea Pharmaceuticals is trading 5.16% up now at $5.00, alongside a broader biotechnology rally. - Biotech ETF XBI is up 2.09%; sentiment is supported by...
Atea Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Atea Pharmaceuticals is projected to report a Q2 2026 loss of $0.56 per share on zero revenue, with the stock currently trading at $4.12 compared to a $12.00...
🟢 Atea Pharmaceuticals is trading 6.4% up today as shares extend rebound amid broader market gains
Atea Pharmaceuticals is trading 6.4% up today at $4.92 as shares extend a rebound from a recent sell-off amid a broader market rally. • The stock is...
🟢 Atea Pharmaceuticals is trading 5.3% up today on a partial snap-back after a sharp decline
Atea Pharmaceuticals is trading 5.3% up at $4.75 as the stock rebounds from a sharp 12.2% decline on July 28. • The previous sell-off occurred on no...
🔴 Atea Pharmaceuticals is trading 12.2% down today, lagging a weak biotech sector on no specific news
Atea Pharmaceuticals is trading at $4.23 (down 12.2%), notably underperforming a declining biotech group and mixed broader indices. • The move appears driven...
🔴 Atea Pharmaceuticals is trading 5.5% down today as it underperforms a rallying biotech sector
Atea Pharmaceuticals is trading 5.5% down at $4.55, underperforming a rallying biotech sector and a mixed broader market despite a lack of fresh...
Atea Pharmaceuticals advances AT-587, targeting first-ever Hepatitis E treatment
Atea Pharmaceuticals launched a first-in-human Phase 1 clinical trial for AT-587. This oral antiviral candidate targets the hepatitis E virus (HEV). No...
🔴 Atea Pharmaceuticals is trading 5.4% down today amid broader biotech weakness and profit-taking
Atea Pharmaceuticals is trading at $4.72 (-5.41%) amid broader biotech sector weakness and profit-taking following a strong rally. • The decline aligns with a...
🔴 Atea Pharmaceuticals Inc is trading 5.01% down in after-hours
AVIR is trading at $4.74, down 5.01% in after-hours.
🔴 AVIR trading 9.4% down despite Phase 3 enrollment completion
AVIR is trading at $4.06 (9.4% down) in pre-market. The company announced today the completion of patient enrollment in its Phase 3 C-FORWARD trial for...
Atea Pharmaceuticals Shareholders Approve All Proposals at 2026 Annual Meeting
Atea Pharmaceuticals announced the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. All proposals presented were approved by the...